Menogaril

Menogaril
Names
Other names
7-O-Methylnogarol
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
UNII
  • InChI=1S/C28H31NO10/c1-27(36)8-10-6-11-16(21(32)15(10)14(9-27)37-5)22(33)17-13(30)7-12-24(18(17)20(11)31)38-26-23(34)19(29(3)4)25(35)28(12,2)39-26/h6-7,14,19,23,25-26,30,32,34-36H,8-9H2,1-5H3/t14-,19+,23+,25-,26-,27-,28-/m1/s1 ☒N
    Key: LWYJUZBXGAFFLP-OCNCTQISSA-N ☒N
  • InChI=1/C28H31NO10/c1-27(36)8-10-6-11-16(21(32)15(10)14(9-27)37-5)22(33)17-13(30)7-12-24(18(17)20(11)31)38-26-23(34)19(29(3)4)25(35)28(12,2)39-26/h6-7,14,19,23,25-26,30,32,34-36H,8-9H2,1-5H3/t14-,19+,23+,25-,26-,27-,28-/m1/s1
    Key: LWYJUZBXGAFFLP-OCNCTQISBR
  • CO[C@@H]1C[C@](C)(O)Cc2cc3c(c(O)c21)C(=O)c1c(O)cc2c(c1C3=O)O[C@@H]1O[C@@]2(C)[C@H](O)[C@@H](N(C)C)[C@@H]1O
Properties
C28H31NO10
Molar mass 541.55 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Menogaril is an anthracycline analog of nogalamycin which was developed in late 1970s. It has even stronger anticancer activity than nogalamycin and has less toxicity than nogalamycin. However, its development for clinical use was cancelled due to only moderate success with relatively high incidence of serious toxicity (43-44% in non-Hodgkin's lymphoma patients).[1]

References

  1. ^ Moore DF Jr; Brown TD; LeBlanc M; Dahlberg S; Miller TP; McClure S; Fisher RI. (1999). "Phase II trial of menogaril in non-Hodgkin's lymphomas: a Southwest Oncology Group trial". Invest New Drugs. 17 (2): 169–72. doi:10.1023/A:1006375301205.


Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.